Attenuation of SARS‐CoV‐2 replication and associated inflammation by concomitant targeting of viral and host cap 2'‐O‐ribose methyltransferases

• Published in: The EMBO journal Vol. 41; no. 17; pp. e111608 - n/a
• Main Authors: Bergant, Valter, Yamada, Shintaro, Grass, Vincent, Tsukamoto, Yuta, Lavacca, Teresa, Krey, Karsten, Mühlhofer, Maria‐Teresa, Wittmann, Sabine, Ensser, Armin, Herrmann, Alexandra, vom Hemdt, Anja, Tomita, Yuriko, Matsuyama, Shutoku, Hirokawa, Takatsugu, Huang, Yiqi, Piras, Antonio, Jakwerth, Constanze A, Oelsner, Madlen, Thieme, Susanne, Graf, Alexander, Krebs, Stefan, Blum, Helmut, Kümmerer, Beate M, Stukalov, Alexey, Schmidt‐Weber, Carsten B, Igarashi, Manabu, Gramberg, Thomas, Pichlmair, Andreas, Kato, Hiroki
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.09.2022; Springer Nature B.V; John Wiley and Sons Inc
• Subjects: Adenosylhomocysteinase; Antiviral activity; Antiviral agents; Antiviral drugs; antivirals; COVID-19; Drug screening; EMBO19; EMBO23; Fibrosis; host‐directed; Immunomodulation; Immunosuppressive agents; Infections; Inhibitors; Methylation; Methyltransferase; Replication; Ribose; SARS‐CoV‐2; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Side effects; Substrate inhibition; Viral diseases; antivirals; methyltransferase; COVID‐19; SARS‐CoV‐2; host‐directed

The SARS‐CoV‐2 infection cycle is a multistage process that relies on functional interactions between the host and the pathogen. Here, we repurposed antiviral drugs against both viral and host enzymes to pharmaceutically block methylation of the viral RNA 2'‐O‐ribose cap needed for viral immune...